Biodexa Pharmaceuticals (BDRX) said Monday that the US Food and Drug Administration granted fast track designation for eRapa to potentially treat familial adenomatous polyposis.
The designation helps facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
The company said it had received US FDA orphan drug designation for eRapa in familial adenomatous polyposis and intends to seek a similar designation in Europe.
Familial adenomatous polyposis universally leads to cancer of the colon and/or rectum if untreated, Biodexa said.
The company's shares were up more than 65% in recent trading.
Price: 6.75, Change: +2.68, Percent Change: +65.85
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.